Kymera Therapeutics (NASDAQ:KYMR) Issues Quarterly Earnings Results, Misses Estimates By $0.06 EPS

Kymera Therapeutics (NASDAQ:KYMR) released its quarterly earnings results on Thursday. The company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.26) by ($0.06), FiscalAI reports. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%. Kymera Therapeutics’s revenue was up .0% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.94) EPS.

Here are the key takeaways from Kymera Therapeutics’ conference call:

• KT-579 showed robust human proof of mechanism: once-daily dosing produced more than 90% IRF5 degradation in the top dose cohorts, including comparable effects in skin, with substantial reductions across inflammatory cytokine, interferon, and B-cell pathways.
• KT-579 was well tolerated in the phase I study, with a safety profile comparable to placebo, no serious adverse events, no discontinuations, and no infection imbalance. Kymera plans to advance the program into the approximately 30-patient LUMORA phase Ib lupus trial by early 2027.
• The company completed the 16-week placebo-controlled portion of the KT-621 BROADEN2 atopic dermatitis study and expects to report results by year-end; 98% of eligible patients entered the 52-week open-label extension. Kymera is preparing for a potential phase III AD study beginning by mid-2027, subject to supportive results and FDA alignment.
• KT-621 asthma enrollment is progressing as planned, with phase IIb BREADTH results expected in late 2027, while partner programs KT-485 and KT-200 also remain on track. Management emphasized potential expansion into additional type 2 inflammatory diseases, but detailed plans will depend on upcoming clinical data.
• Kymera ended September with approximately $1.6 billion in cash and investments, providing a projected runway into 2029 and funding planned KT-621 phase III preparations, the KT-579 lupus study, and continued pipeline research without near-term financing pressure.

Kymera Therapeutics Stock Down 0.7%

Shares of KYMR traded down $0.80 during trading hours on Thursday, hitting $121.71. The company had a trading volume of 645,629 shares, compared to its average volume of 746,868. The firm has a market cap of $10.12 billion, a P/E ratio of -37.53 and a beta of 1.98. The stock’s 50 day moving average price is $114.92 and its 200 day moving average price is $95.84. Kymera Therapeutics has a 52-week low of $55.66 and a 52-week high of $130.05.

Analyst Ratings Changes

Several analysts have issued reports on KYMR shares. Morgan Stanley boosted their target price on Kymera Therapeutics from $135.00 to $146.00 and gave the company an “overweight” rating in a research note on Tuesday. Wolfe Research upgraded shares of Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $180.00 target price for the company in a research note on Thursday, September 10th. Brookline Capital Markets reiterated a “buy” rating on shares of Kymera Therapeutics in a research report on Thursday. Raymond James Financial reiterated an “outperform” rating on shares of Kymera Therapeutics in a research note on Thursday. Finally, TD Cowen raised Kymera Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $135.12.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, CEO Nello Mainolfi sold 30,000 shares of the stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $113.80, for a total value of $3,414,000.00. Following the completion of the transaction, the chief executive officer owned 666,568 shares in the company, valued at approximately $75,855,438.40. This represents a 4.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Brian Adams sold 6,371 shares of Kymera Therapeutics stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $116.83, for a total transaction of $744,323.93. Following the transaction, the insider directly owned 50,254 shares of the company’s stock, valued at approximately $5,871,174.82. This trade represents a 11.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 15.98% of the company’s stock.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins through targeted protein degradation. Its approach is designed to use the cell’s natural protein-disposal system to remove proteins that may be difficult to address with conventional drug modalities.

The company’s research and development programs have targeted a range of disease areas, including immune-mediated and inflammatory conditions, cancer, and other serious illnesses.